Differential binding of plasma proteins by liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the bilayer

Biochemistry (Moscow)

Volumn 79, Issue 8, 2014, Pages 797-804

  Kuznetsova, N R ^a   Vodovozova, E L ^a  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

antitumor liposomes; complement; lipophilic prodrugs; melphalan; methotrexate; nanomedicine; protein corona

Indexed keywords

COMPLEMENT COMPONENT C3; LIPID BILAYER; LIPOSOME; MELPHALAN; METHOTREXATE; PLASMA PROTEIN; PRODRUG;

CHEMICAL PHENOMENA; CHEMISTRY; ENZYME SPECIFICITY; HUMAN; LIPID BILAYER; METABOLISM;

BLOOD PROTEINS; COMPLEMENT C3; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIPID BILAYERS; LIPOSOMES; MELPHALAN; METHOTREXATE; PRODRUGS; SUBSTRATE SPECIFICITY;

EID: 84906220638     PISSN: 00062979     EISSN: 16083040     Source Type: Journal    
DOI: 10.1134/S0006297914080070     Document Type: Article

References (39)

1. Monopoli, M. P.; Aberg, C.; Salvati, A.; and Dawson, K. A. (2012) Biomolecular coronas provide the biological identity of nanosized materials, Nat. Nanotech.; 7, 779-786.
2. Walkey, C. D.; and Chan, W. C. W. (2012) Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment, Chem. Soc. Rev.; 41, 2780-2799.
3. Aggarwal, P.; Hall, J. B.; McLeland, C. B.; Dobrovolskaia, M. A.; and McNeil, S. E. (2009) Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy, Adv. Drug Deliv. Rev.; 61, 428-437.
4. Semple, S. C.; Chonn, A.; and Cullis, P. R. (1998) Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behavior in vivo, Adv. Drug Deliv. Rev.; 32, 3-17.
5. Dobrovolskaia, M. A.; Neun, B. W.; Man, S.; Ye, X.; Hansen, M.; Patri, A. K.; Crist, R. M.; and McNeil, S. E. (2014) Protein corona composition does not accurately predict hematocompatibility of colloidal gold nanoparticles, Nanomedicine, doi: 10.1016/j.nano.2014.01.009.
6. Chonn, A.; Semple, S. C.; and Cullis, P. R. (1992) Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes, J. Biol. Chem.; 267, 18759-18765.
7. Szebeni, J. (2012) Hemocompatibility testing for nanomedicines and biologicals: predictive assays for complement mediated infusion reactions, Eur. J. Nanomed.; 4, 33-53.
8. Szebeni, J.; Muggia, F.; Gabizon, G.; and Barenholz, Y. (2011) Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention, Adv. Drug Deliv. Rev.; 63, 1020-1030.
9. Szebeni, J.; Muggia, F. M.; and Alving, C. R. (1998) Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study, J. Natl. Cancer Inst.; 90, 300-306.
10. Kuznetsova, N.; Kandyba, A.; Vostrov, I.; Kadykov, V.; Gaenko, G.; Molotkovsky, J.; and Vodovozova, E. (2009) Liposomes loaded with lipophilic prodrugs of methotrexate and melphalan as convenient drug delivery vehicles, J. Drug Deliv. Sci. Technol.; 19, 51-59.
11. Vodovozova, E. L.; Moiseeva, E. V.; Grechko, G. K.; Gayenko, G. P.; Nifant'ev, N. E.; Bovin, N. V.; and Molotkovsky, J. G. (2000) Antitumor activity of cytotoxic liposomes equipped with selectin ligand SiaLeX, in a mouse mammary adenocarcinoma model, Eur. J. Cancer, 36, 942-949.
12. Kozlov, A. M.; Korchagina, E. Yu.; Vodovozova, E. L.; Bovin, N. V.; Molotkovskii, Yu. G.; and Syrkin, A. B. (1997) Increase in sarcolysin antitumor activity by transforming it into a lipid derivative and incorporation into the membrane of liposomes containing a carbohydrate vector, Byul. Eksp. Biol. Med.; 123, 381-383.
13. Kuznetsova, N. R.; Sevrin, C.; Lespineux, D.; Bovin, N. V.; Vodovozova, E. L.; Meszaros, T.; Szebeni, J.; and Grandfils, C. (2012) Hemocompatibility of liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the lipid bilayer, J. Control Rel.; 160, 394-400.
14. Heiss, H. W. (1983) in Human Physiology (Schmidt, R. F.; and Thews, G.; eds.) Springer-Verlag, Berlin-Heidelberg-New York, pp. A43-A44.
15. Vodovozova, E. L.; Nikol'skii, P. Yu.; Mikhalev, I. I.; and Molotkovskii, Yu. G. (1996) Lipid derivatives of sarcolysin, methotrexate, and rubomycin, Russ. J. Bioorg. Chem.; 22, 468-475.
16. Vodovozova, E. L.; Gaenko, G. P.; Bobrikova, E. S.; Pazynina, G. V.; and Molotkovskii, Yu. G. (2007) A diglyceride derivative of methotrexate: synthesis and cytotoxic activity in targeted delivery liposomes, Pharm. Chem. J.; 41, 297-301.
17. Markwell, M.; Haas, S.; and Bieber, L. (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples, Anal. Biochem.; 210, 206-210.
18. Dos Santos, N.; Allen, C.; Doppen, A.-M.; Anantha, M.; Cox, K.; Gallagher, R. C.; Karlsson, G.; Edwards, K.; Kenner, G.; Samuels, L.; Webb, M. S.; and Bally, M. B. (2007) Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding, Biochim. Biophys. Acta, 1768, 1367-1377.
19. Laemmli, U. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature, 227, 680-685.
20. Shevchenko, A.; Wilm, M.; Vorm, O.; and Mann, M. (1996) Mass spectrometric sequencing of proteins silverstained polyacrylamide gels, Anal. Chem.; 68, 850-858.
21. Gabizon, A.; and Papahadjopoulos, D. (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors, Proc. Natl. Acad. Sci. USA, 85, 6949-6953.
22. Peng, A.; Straubinger, R. M.; and Balu-Iyer, S. V. (2010) Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice, AAPS J.; 12, 473-481.
23. Moghimi, S. M.; Andersen, A. J.; Hashemi, S. H.; Lettiero, B.; Ahmadvand, D.; Hunter, A. C.; Andresen, T. L.; Hamad, I.; and Szebeni, J. (2010) Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead, J. Control Rel.; 146, 175-181.
24. Cedervall, T.; Lynch, I.; Lindman, S.; Berggard, T.; Thulin, E.; Nilsson, H.; Dawson, K. A.; and Linse, S. (2007) Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles, Proc. Natl. Acad. Sci. USA, 104, 2050-2055.
25. Vroman, L.; Adams, A.; Fischer, G.; and Munoz, P. (1980) Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces, Blood, 55, 156-159.
26. Goppert, T. M.; and Muller, R. H. (2005) Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting, Int. J. Pharm.; 302, 172-186.
27. Sahu, A.; and Lambris, J. D. (2001) Structure and biology of complement protein C3, a connecting link between innate and acquired immunity, Immunol. Rev.; 180, 35-48.
28. Soames, C. J.; and Sim, R. B. (1997) Interactions between human complement components factor H, factor I and C3b, Biochem. J.; 326, 553-561.
29. Jozsi, M.; Manuelian, T.; Heinen, S.; Oppermann, M.; and Zipfel, P. F. (2004) Attachment of the soluble complement regulator factor H to cell and tissue surfaces: relevance for pathology, Histol. Histopathol.; 19, 251-258.
30. Rodriguez de Cordoba, S.; Esparza-Gordillo, J.; Goicoechea de Jorge, E.; Lopez-Trascasa, M.; and Sanchez-Corral, P. (2004) The human complement factor H: functional roles, genetic variations and disease associations, Mol. Immunol.; 41, 355-367.
31. Price, M. E.; Cornelius, R. M.; and Brash, J. L. (2001) Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma, Biochim. Biophys. Acta, 1512, 191-205.
32. Aramaki, Y.; Akiyama, K.; Hara, T.; and Tsuchiya, S. (1995) Recognition of charged liposomes by rat peritoneal and splenic macrophages: effects of fibronectin on the uptake of charged liposomes, Eur. J. Pharm. Sci.; 3, 63-70.
33. Rodrigueza, W. V.; Phillips, M. C.; and Williams, K. J. (1998) Structural and metabolic consequences of liposome-lipoprotein interactions, Adv. Drug Deliv. Rev.; 32, 31-43.
34. Saito, Y. M.; Handa, T.; and Miyajima, K. (1997) Effect of cholesterol on apolipoprotein A-I binding to lipid bilayers and emulsions, J. Lipid Res.; 38, 287-294.
35. Pham, C. T. N.; Mitchell, L. M.; Huang, J. L.; Lubniewski, C. M.; Schall, O. F.; Killgore, J. K.; Pan, D.; Wickline, S. A.; Lanza, G. M.; and Hourcade, D. E. (2011) Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces, J. Biol. Chem.; 286, 123-130.
36. Janssen, B. J. C.; Christodoulidou, A.; McCarthy, A.; Lambris, J. D.; and Gros, P. (2006) Structure of C3b reveals conformational changes that underlie complement activity, Nature, 444, 213-216.
37. Moghimi, S. M.; Andersen, A. J.; Ahmadvand, D.; Wibroe, P. P.; Andresen, T. L.; and Hunter, C. (2011) Material properties in complement activation, Adv. Drug Deliv. Rev.; 63, 1000-1007.
38. Devine, D. V.; and Marjan, J. M. (1997) The role of immunoproteins in the survival of liposomes in the circulation, Crit. Rev. Ther. Drug Carrier Syst.; 14, 105-131.
39. Devine, D. V.; Wong, K.; Serrano, K.; Chonn, A.; and Cullis, P. R. (1994) Liposome-complement interactions in rat serum: implications for liposome survival studies, Biochim. Biophys. Acta, 1191, 43-51.